

# Gender Differences in Plasma Levels of Lipoprotein (a) in Patients with Angiographically Proven Coronary Artery Disease

J. FROHLICH<sup>1</sup>, M. DOBIÁŠOVÁ<sup>2</sup>, L. ADLER<sup>1</sup>, M. FRANCIS<sup>1</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Healthy Heart Program/Lipid Clinic, St. Paul's Hospital, Vancouver B.C., Canada,

<sup>2</sup>Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received July 22, 2003

Accepted November 6, 2003

---

## Summary

The objective of the study was to assess the association between plasma levels of lipoprotein(a) [Lp(a)] and the presence of angiographically defined coronary artery disease (aCAD). Patients (346 men and 184 women) undergoing selective coronary angiography (SCA) were classified into groups with positive [aCAD(+)] and negative [aCAD(-)] findings and their age, body mass index (BMI), waist circumference, blood pressure, smoking, plasma total, LDL-, HDL-cholesterol (TC, LDL-C, HDL-C), triglycerides (TG), apolipoprotein B (apoB), Log(TG/HDL-C) and TC/HDL-C were determined. Concentration of plasma Lp(a) was estimated using the commercial solid phase two-side immunoradiometric assay of apolipoprotein apo(a). The plasma Lp(a) was significantly higher in both women and men with aCAD(+) compared to those with aCAD(-). While there was no significant difference in the Lp(a) level between men and women with aCAD(-) (median 138 vs. 145 units/l), the women with aCAD(+) had almost twice as high Lp(a) levels as men (median 442 vs. 274 units/l,  $p < 0.001$ ). Women with aCAD(+) had also significantly lower HDL cholesterol levels (1.09 vs. 1.20 mmol/l,  $p < 0.05$ ), higher triglycerides (1.82 vs. 1.46 mmol/l,  $p < 0.05$ ) and Log(TG/HDL-C) than women with aCAD(-). The differences in Lp(a) between positive and negative findings remained highly significant ( $p < 0.001$  in women,  $p < 0.05$  in men) after the adjustment for age, plasma HDL- and LDL-cholesterol and triglycerides in logistic regression analyses. In logistic regression model the Lp(a) and Log(TG/HDL-C) and smoking in women but smoking and age in men were the most powerful predictors of positive aCAD findings. Our findings suggest that Lp(a) is more strongly associated with aCAD+ in women than in men.

---

## Key words

Lipoprotein(a) • Gender • Coronary artery disease • Coronary angiography • Immunoradiometric assay

## Introduction

Concentration of Lp(a) in the plasma is a

significant and independent risk factor for coronary artery disease (CAD) (Dahlen *et al.* 1986, Marcovina *et al.* 1996, Morrisett 2000, Smith *et al.* 2000).

Lp(a) atherogenicity appears to be related to the mechanism of LDL entrapment in the atheroma (Lundstam *et al.* 1999), possibly to the initiation of the proteolytic process responsible for extracellular matrix degradation (Bdeir *et al.* 1999, Ganne *et al.* 1999) and to its competitive inhibition of plasminogen that impairs the thrombolytic processes (Soulat *et al.* 1999).

There is a significant correlation between the plasma concentration of Lp(a) and the extent of coronary artery disease (Dangas *et al.* 1999). In the *Prevention Conference V* Lp(a) was classified as a "conditional" risk factor for atherosclerosis (Smith *et al.* 2000) because of the fact that its significance as a risk factor increases in patients with LDL-C levels over 3 mmol/l (Brown *et al.* 1990, Cremer *et al.* 1994). Most of the Lp(a) studies have been carried out in men and the data in women are limited. However, the Framingham Heart Study found Lp(a), measured as sinking pre-beta lipoprotein on electrophoresis, to be a strong predictor of myocardial infarction, intermittent claudication, and cerebral vascular disease in women (Bostom *et al.* 1994). Another study has shown that Lp(a) was a significant risk factor for CAD in both pre- and postmenopausal women (Orth-Gomer *et al.* 1997).

In the present study, we investigated plasma Lp(a) levels in men and women (patients of Vancouver teaching hospitals) undergoing to selective coronary angiography to assess the associations between Lp(a) concentration and actual angiography findings in men and women.

## Methods

### Patients

Patients were recruited amongst individuals undergoing selective coronary angiography at two teaching hospitals in Vancouver (St. Paul's and Vancouver General). Participants of the study were mostly of European background (there were no Afro-Americans). The indications for angiography included exercise-induced chest pain, previously diagnosed myocardial infarction, atypical chest pain, aortic stenosis/regurgitation and mitral regurgitation. Patients with unstable angina and myocardial infarction within the preceding two months were excluded from the study. More than 85 % of women in this study were in menopause. Among patients of both gender with positive SCA 20 % had diabetes.

All participants signed a consent form approved

by the Ethics Committees of both hospitals and University of British Columbia. All patients were asked to fill in a questionnaire under a nurse's or physician's supervision. This included demographic data, history of vascular disease, family history and presence of major risk factors for CAD. Height, weight and abdominal circumference were measured at the same time.

Coronary angiograms were obtained by the standard techniques with multiple aspects recorded and evaluated by the cardiologists. The angiograms were defined as to the number of vessels involved (0, 1, 2 or 3) and as to the severity of lesions, namely greater or smaller than 50% lumen obstruction. For the purpose of this study any angiograms without any positive findings were defined as "negative".

### Laboratory assays

Plasma lipids were measured after an overnight fasting in a venous blood sample collected into EDTA-containing vacutainers on the day of the angiogram. The blood was kept at 4 °C, spun within 12 h and aliquots of plasma were frozen at -70 °C until analyses carried out 3 years later. Plasma total cholesterol (TC), triglycerides (TG) and HDL-cholesterol (HDL-C) were measured enzymatically. LDL cholesterol (LDL-C) was calculated according to the Friedewald equation, apolipoprotein B (apoB) was measured nephelometrically (Beckman Array System). Lp(a) concentration was measured using a solid phase two-sided immunoradiometric assay (Mercoxia apo(a) RIA, Mercoxia AB, Uppsala, Sweden) of apolipoprotein apo(a). Lp(a) assay quality control was monitored by Canadian Reference Laboratory, the coefficient of variations was 12% and 12.5% at 130 and 350 IU/l, respectively.

### Statistical analysis

Statistical package (SPSS Base11.0) was used to analyze the data. Multiple logistic regression analysis was used to discriminate between dependent and independent variables. Lp(a) data, because of their extreme skewness, were evaluated by the Mann-Whitney U test.

## Results

Of the 184 women and 346 men in whom Lp(a) was measured, 136 women (mean age 64 years) and 297 men (61 years) had angiographic evidence of CAD (aCAD+), while 48 women (62 years) and 49 men (57 years) had no angiographic evidence of CAD


[aCAD(-)]. As shown in Table 1, there were no significant differences between women with or without angiographic evidence of CAD in age, body mass index, concentration of total plasma cholesterol and apoB. Women with aCAD(+) had slightly higher triglycerides, LDL-cholesterol and lower HDL-cholesterol levels compared to aCAD(-), while the two groups of men

differed in age only. There were several significant differences between men and women (Table 1). Women were older than men in both aCAD groups; plasma cholesterol, HDL- and LDL-cholesterol and apoB were higher in women compared to men with aCAD(+), while in those with aCAD(-) the only difference was in higher concentration of HDL-C in women.

**Table 1.** Characteristics of women and men with positive (aCAD+) and negative (aCAD-) angiography findings, lipid concentrations in mmol/l.

	WOMEN		P=	MEN		P=	WOMEN vs. MEN	
	aCAD(+) n=136	aCAD(-) n=48		aCAD(+) n=297	aCAD(-) n=49		aCAD(+) P=	aCAD(-) P=
Age	64.2±10.1	62.3±7.3	N.S.	60.9±9.5	56.8±10.2	0.02	0.001	0.002
BMI	27.7±5.5	26.8±4.4	N.S.	28.3±4.3	28.3±5.6	N.S.	N.S.	N.S.
TC	5.52±1.11	5.28±1.09	N.S.	5.06±0.99	5.08±1.07	N.S.	0.001	N.S.
TG	1.82±1.00	1.46±0.75	0.025	1.88±1.37	1.87±1.23	N.S.	N.S.	N.S.
LDL-C	3.84±1.07	3.46±1.10	0.041	3.30±0.83	3.58±0.99	N.S.	0.001	N.S.
HDL-C	1.09±0.29	1.20±0.35	0.036	0.92±0.22	0.92±0.25	N.S.	0.001	0.001
APOB	1.02±0.27	0.94±0.26	N.S.	0.94±0.22	0.89±0.22	N.S.	0.001	N.S.
Log(TG/HDL-C)	0.19±0.27	0.06±0.25	0.000	0.25±0.29	0.24±0.28	N.S.	0.036	0.001
TC/HDL/C	5.5±1.9	4.8±1.7	0.032	5.8±2.2	5.8±1.8	N.S.	N.S.	0.007

Data are mean ± SD.



**Fig. 1.** Lipoprotein(a) (median values) of women and men with positive (aCAD+) and negative (aCAD-) angiography findings.

Most pronounced differences between aCAD(+) and aCAD(-) patients were found in plasma concentration of Lp(a). There was significantly higher plasma Lp(a) level (Fig. 1) in both women (median 442 units/l) and men (274 units/l) with aCAD(+)

compared to those with aCAD(-) (141 and 148 units/l, respectively). However, median Lp(a) levels were significantly higher in women compared to men with aCAD(+) ( $p < 0.001$ , Mann-Whitney U test). There was no significant difference in Lp(a) levels between men and women without angiographic evidence of CAD. The differences in Lp(a) between aCAD(+) and aCAD(-) remained significant ( $p < 0.001$  in women,  $p < 0.05$  in men) after the adjustment for age, plasma HDL- and LDL-cholesterol and triglycerides.

No associations between plasma Lp(a) and age, BMI, TC, TG, HDL-C and apoB (Table 2) were found in men. However, significant correlations were found between Lp(a) and plasma cholesterol, LDL cholesterol and apo B in women (Table 2). The correlation between Lp(a) and aCAD remained highly significant even after the adjustment for cholesterol in partial correlation analysis. There was no correlation between plasma Lp(a) level and diabetes or positive family history for CAD.

Table 3 shows the results of logistic regression analysis of the differences between aCAD(+) and aCAD(-) groups. In the multivariate logistic regression model, which included parameters such as age, BMI,

smoking, TC, TG, LDL-C, apoB, HDL-C, Lp(a), Log(TG/HDL-C) and TC/HDL-C, the most powerful predictors of aCAD(+) in women were Lp(a), Log(TG/HDL-C) and smoking, while in men the predictors were smoking and age.

**Table 2.** Pearson correlation analysis between Lp(a) and other parameters

	Women	Men
Age	0.141	0.060
BMI	-0.016	-0.058
TC	0.211**	0.038
TG	-0.047	-0.042
LDL-C	0.267**	0.043
HDL-C	-0.050	-0.097
APOB	0.242**	0.091

\*\*Correlation is significant at the  $p < 0.01$  level (2-tailed).

**Table 3.** Multivariate regression model for women and men.

	Independent predictor of aCAD(+)	Exp(B)	95 % C.I. for Exp(B) (lower – upper)	P-value
WOMEN	Lp(a)	1.002	(1.001 – 1.003)	0.000
	Log(TG/HDL/C)	6.785	(1.618 – 23.741)	0.009
	Smoking	2.191	(1.016 – 4.723)	0.046
MEN	Smoking	3.752	(1.920 – 7.334)	0.000
	Age	1.041	(1.005 – 1.078)	0.024

Model variables: Age, BMI, smoking, TC, TG, LDL-C, ApoB, HDL-C, Lp(a), Log(TG/HDL-C), TC/HDL-C. Exp(B) – estimated odds ratio, C.I. – confidence interval for Exp(B)

The purpose of this study was to determine whether a routine assessment of Lp(a) in patients at risk of CHD further adds to their risk assessment. The objective correlate of disease in our study were the findings on coronary angiography. These were correlated with the plasma concentration of Lp(a) and routine lipids. All our patients were of European descent and therefore more comparable with regard to Lp(a) isoforms than, for instance, Caucasian and African American populations. In our medium sized cohort of patients the routine lipid profile had fairly low predictive value for positive angiographic findings. In men, the differences in lipid parameters between those with aCAD(+) and aCAD(-) were not statistically significant, while women with aCAD(+) had higher LDL-C, TG and lower HDL-C

## Discussion

There is a prevailing consensus that Lp(a) is predictive of both the severity and extent of CAD (Budde *et al.* 1994, Weber *et al.* 1997, Wilson *et al.* 1999) in a number of different populations including Blacks and Whites (Guyton *et al.* 1985, Marcovina and Koschinski 2000, Paultre *et al.* 2000). On the other hand, several studies including the Quebec Cardiovascular Study in men (Cantin *et al.* 1998), other studies from U.S. (Nguyen *et al.* 1997) and Finland (Salomaa *et al.* 1994) failed to show any relation between Lp(a) and CAD. While some reports show higher predictive value for CAD of low molecular weight apolipoprotein(a) isoforms (Gazzaruso *et al.* 1998), others report indicate that the apo(a) phenotypes are distributed similarly in subjects with and without atherosclerosis and are related to other risk factors in both men and women (Bowden *et al.* 1994).

The Log(TG/HDL) index which well correlates with other risk factors for CAD as recently reported (Dobiášová and Frohlich 2001), was also significantly increased in women with aCAD(+). There were no significant differences in the Lp(a) plasma level between men and women with negative angiography, while the women with positive findings had Lp(a) levels almost twice as high as men. The multivariate analysis has confirmed that in women plasma Lp(a) besides of Log(TG/HDL) and smoking was a significant independent predictor of positive findings on angiography.

Our findings suggest that Lp(a) measurement is of value in investigation of patients at risk for CAD and that it is a particularly useful predictor of risk in women.

## Acknowledgements

We are grateful to Dr Scott Lear for help with statistical analyses. This study was supported by grants from British

Columbia Heart & Stroke Foundation and grant from the Ministry of Health of the Czech Republic no.NA/6590-3.

## References

- BDEIR K, CANE W, CANZIANI G, CHAIKEN I, WEISEL J, KOSCHINSKY ML, LAWN RM, BANNERMAN PG, SACHAIS BS, KUO A, HANCOCK MA, TOMASZEWSKI J, RAGHUNATH PN, GANZ T, HIGAZI AA, CINES DB: Defensin promotes the binding of lipoprotein(a) to vascular matrix. *Blood* **94**: 2007-2019, 1999.
- BOSTOM, GAGNON DR, CUPPLES, WILSON PW, JENNER JL, ORDOVAS JM, SCHAFER EJ, CASTELLI A: Prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. *Circulation* **90**: 1688-1695, 1994.
- BOWDEN JF, PRITCHARD PH, HILL JS, FROHLICH JJ: Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. *Arterioscler Thromb* **14**: 1561-1568, 1994.
- BROWN G, ALBERS JJ, FISHER LD, SCHAEFER SM, LIN JT, KAPLAN C, ZHAO XQ, BISSON BD, FITZPATRICK VF, DODGE HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* **323**: 1289-1298, 1990.
- BUDDE T, FECHTRUP C, BOSENBERG E, VIELHAUER C, ENBERGS A, SCHULTE H, ASSMANN G, BREITHARDT G: Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. *Arterioscler Thromb* **14**: 1730-1436, 1994.
- CANTIN B, GAGNON F, MOORJANI S, DESPRES JP, LAMARCHE B, LUPIEN PJ, DAGENAIS GR: Is Lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. *J Am Coll Cardiol* **31**: 519-525, 1998.
- CREMER P, NAGEL D, LABROT B, MANN H, MUCHE R, ELSTER H, SEIDEL D: Lipoprotein(a) as predictor of myocardial infarction in comparison with fibrinogen, LDL cholesterol and other risk factors: results from prospective Gottingen Risk Incidence and Prevalence Study. *Eur J Clin Invest* **24**: 444-453, 1994.
- DAHLEN GH, GUYTON JR, ATTAR M, FARMER JA, KAUTZ JA, GOTTO AM Jr: Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease, documented by angiography. *Circulation* **74**: 758-765, 1986.
- DANGAS G, AMBROSE JA, D'AGATE DJ: Correlation of plasma lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. *Am J Cardiol* **83**: 583-585, 1999.
- DOBIÁŠOVÁ M, FROHLICH J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER<sub>HDL</sub>). *Clin Biochem* **34**: 583-588, 2001.
- GANNE F, VASSE M, BEAUDEUX JL, PEYNET J, FRANCOIS A, PAYSANT J, LENORMAND B, COLLET JP, VANNIER JP, SORIA J, SORIA C: Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins: consequences for plasmin generation and monocyte adhesion. *Thromb Haemost* **81**: 594-600, 1999.
- GAZZARUSSO C, GARZANITI A, BUSCAGLIA P, BONETTI G, FALCONE C, FRATINO P, FINARDI G, GEROLDI D: Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of lipoprotein(a) polymorphism. *J Cardiovasc Risk* **5**: 37-42, 1998.
- GUYTON JR, DAHLEN GH, PATSCH W, KAUTZ JA, GOTTO AM Jr: Relationship of plasma lipoprotein(a) levels to race and to apoprotein B. *Arteriosclerosis* **5**: 265-272, 1985.
- LUNDSTAM U, HURT-CAMEJO E, OLSSON G, SARTIPY P, CAMEJO G, WIKLUND O: Proteoglycans contribution on association of Lp(a) and LDL with smooth muscle cell extracellular matrix. *Arterioscler Thromb Vasc Biol* **19**: 1162-1167, 1999.

- MARCOVINA SA, KOSCHINSKY ML: Lipoprotein(a): Structure, measurement, and clinical significance. In *Handbook of Lipoprotein Testing*, RIFAI N, .WARNICK RG, DOMINICZAK MH (eds), AACC Press, Washington, DC, 2000, pp 345-386.
- MARCOVINA SM, ALBERS JJ, WIJSMAN E, ZHANG Z-H, CHAPMAN NH, KENNEDY H: Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. *J Lipid Res* **37**: 2569-2585,1996.
- MORRISETT JD: The role of lipoprotein(a) in atherosclerosis. *Curr Atheroscler Rep* **2**: 243- 250, 2000.
- NGUYEN TT, ELLEFSON RD, HODGE DO, BAILEY KR, KOTTKE TE, ABU-LEBDEH HS: Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. *Circulation* **96**: 1390-1397, 1997.
- ORTH-GOMER K, MITTLEMAN MA, SCHENCK-GUSTAFSSON K, WAMALA SP, ERIKSSON M, BELKIE K, KIRKEEIDE R, SVANE B, RYDEN L: Lipoprotein(a) as a determinant of coronary heart disease in young women. *Circulation* **95**: 329-334, 1997.
- PAULTRE F, PEARSON TA, WEIL HF, TUCK CH, MYERSON M, RUBIN J, FRANCIS CK, MARX HF, PHILBIN EF, REED RG, BERGLUND L: High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. *Arterioscler Thromb Vasc Biol* **20**: 2619-2624, 2000.
- SALOMAA V, RASI V, PEKKANEN J, VAHTERA E, JAUHAINEN M, VARTIAINEN E, MYLLYLÄ G, EHNHOLM C: Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. *Eur Heart J* **15**: 1293-1299, 1994.
- SMITH SC, GREENLAND P, GRUNDY SM: Prevention conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive summary. *Circulation* **101**: 111-116, 2000.
- SOULAT T, LOYAU S, BAUDOIN V, DURLACH V, GILLERY P, GARNOTEL R, LOIRAT C, ANGLES CANO E: Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin: a study with individual plasmas presenting natural variations of Lp(a). *Thromb Haemost* **82**: 121-127, 1999.
- WEBER M, McNICOLL S, MARCIL M, CONNELLY P, LUSSIER-CACAN S, DAVIGNON J, LATOUR Y, GENEST J Jr: Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature artery disease in French Canadians. *Can J Cardiol* **13**: 253-260, 1997.
- WILSON SH, CELERMAJER DS, NAKAGOMI A, WYNDHAM RN, JANU MR, BEN FREEDMAN S: Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. *Coron Artery Dis* **10**: 449-453, 1999.

---

**Reprint requests**

Milada Dobiášová, PhD, DSc, Institute of Physiology, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague 4, 142 20 Czech Republic, e-mail: [dobias@biomed.cas.cz](mailto:dobias@biomed.cas.cz)